Ionetix Corp / DE / — SEC Form D Filing

Ionetix Corp / DE / filed an SEC Form D on April 23, 2026, reporting $32.33M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
April 23, 2026
Amount reported
$32.33M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.ionetix.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

There is a need for advanced diagnostics and therapeutic radiopharmaceuticals to improve the detection and treatment of conditions such as coronary artery disease (CAD) and cancer.

Solution

Ionetix provides radiopharmaceutical production and manufacturing solutions, including N13 Ammonia for PET imaging of CAD and targeted alpha therapy for cancer treatment using alpha radionuclides.

Why now

The increasing demand for advanced diagnostics and therapeutic options in healthcare makes Ionetix's offerings timely and necessary.

Verdict

Investors said yes to Ionetix Corp's narrative because the healthcare sector's urgent need for innovative diagnostics and therapies aligned with the company's promise of precision radiopharmaceuticals, not because of a clearly defined competitive edge. The implicit bet was on the increasing acceptance and integration of targeted therapies in clinical settings to improve patient outcomes. However, the limited upside arises from the crowded landscape of competing firms and the challenge of distinguishing Ionetix's offerings amidst established players, suggesting that durability might be challenged.

Source: SEC EDGAR Form D filing